צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים: Accelerate Diagnostics (AXDX)

The slow integration of Pheno systems into clinics is leading to losses and capital deficits for Accelerate Diagnostics (AXDX). This chart from GURU.Markets illustrating quarterly EPS growth demonstrates a sideways trend, where 0.00 represents the latest metric reading. Revenues are based on the sale of equipment and reagents, while the sale of resistance test cards generates recurring revenue, enhancing FCF potential.

This indicator assesses the quarterly dynamics of earnings per share, reflecting the efficiency of value generation and the rate of change in asset yield. By analyzing the quarter-over-quarter growth in earnings per share, an investor can see the critical dependence of Accelerate Diagnostics (AXDX) on the adoption rates of Pheno systems, where a negative trajectory of the curve confirms an operational deficit and the risk of liquidity depletion for the company.